Changes in peripheral lymphocyte populations in patients with advanced/recurrent ovarian cancer undergoing splenectomy during cytoreductive surgery

Table 1 Demographic and clinicopathological information (n = 83)

Variables	Splenectomy (n = 20)	Non-splenectomy (n = 63)	P-value
Age (years), mean (SD, 95% CI)	58 (9.7, 53–62)	54 (8.8, 52–56)	0.114^*
Neoadjuvant chemotherapy (%)	2 (10%)	0	0.056^#
Histology
High-grade serous carcinoma	18 (90.0%)	55 (87.3%)	0.246^#
Clear cell carcinoma	0	5 (7.9%)
Endometrioid	1 (5.0%)	1 (1.6%)
Carcinosarcoma	1 (5.0%)	0
Low-grade serous carcinoma	0	2 (3.2%)
Pre-treatment CA125 (U/mL), media (range)	718.9 (8.9–5000) ^a	539.0 (8.3–5000)	0.446^**
FIGO stage (%)
IIIC	11 (55.0%)	33 (52.4%)	0.838^#
IV	3 (15.0%)	14 (22.2%)
Recurrence	6 (30.0%)	16 (25.4%)
Residual disease (%)
0	13 (65.0%)	40 (63.5%)	0.903^#
≤ 1 cm (optimal)	7 (35.0%)	23 (36.5%)	0.903^#
Platinum response (%) ^b
Sensitive	14 (70.0%)	51 (81.0%)	0.185^#
Resistant	6 (30.0%)	9 (14.3%)	0.185^#

P-value < 0.05 was deemed statistically significant
Abbreviations: FIGO The International Federation of Gynecology and Obstetrics, CA125 Cancer Antigen 125
^a The upper limit of CA 125 detection is 5000
^b Sixteen patients in the splenectomy group and 40 patients in the control group were available for platinum response assessment
^* Independent-Sample T-test
^** Mann–Whitney U test
^# chi-square or Fisher’s exact test

ISSN: 1757-2215